| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $18,970 | 6 | 100 |
Sells | $0 | 0 | 0 |
| Michel Robert J | Chief Financial Officer | 2 | $9,900 | 0 | $0 | $9,900 |
| Feldschuh Michael Richard | Chief Executive Officer | 1 | $9,070 | 0 | $0 | $9,070 |
| Feldschuh Jonathan Adam | Chief Scientific Officer | 1 | $0 | 0 | $0 | $0 |
| Jefferies John | Chief Medical Officer | 2 | $0 | 0 | $0 | $0 |
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
Over the last 12 months, insiders at Daxor Corporation have bought $18,970 and sold $0 worth of Daxor Corporation stock.
On average, over the past 5 years, insiders at Daxor Corporation have bought $49,539 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Michel Robert J (Chief Financial Officer) — $9,900. Feldschuh Michael Richard (Chief Executive Officer) — $9,070.
The last purchase of 1,000 shares for transaction amount of $9,070 was made by Feldschuh Michael Richard (Chief Executive Officer) on 2026‑04‑08.
| 2026-04-08 | Feldschuh Michael Richard | Chief Executive Officer | 1,000 0.0203% | $9.07 | $9,070 | +13.61% | ||
| 2026-03-31 | Michel Robert J | Chief Financial Officer | 1,000 0.0203% | $9.90 | $9,900 | +5.54% | ||
| 2026-03-20 | Jefferies John | Chief Medical Officer | 5,941 – | $0 | $0 | -7.11% | ||
| 2025-12-09 | Feldschuh Jonathan Adam | Chief Scientific Officer | 18,000 – | $0 | $0 | -8.92% | ||
| 2025-12-09 | Michel Robert J | Chief Financial Officer | 3,000 – | $0 | $0 | -8.92% | ||
| 2025-11-12 | Jefferies John | Chief Medical Officer | 2,344 – | $0 | $0 | -6.45% | ||
| 2025-04-04 | Feldschuh Michael Richard | Chief Executive Officer | 2,063 0.044% | $7.89 | $16,277 | +49.02% | ||
| 2025-03-10 | Feldschuh Michael Richard | Chief Executive Officer | 3,360 0.0688% | $7.68 | $25,805 | +46.52% | ||
| 2025-03-10 | Michel Robert J | Chief Financial Officer | 1,000 0.0213% | $8.00 | $8,000 | +46.52% | ||
| 2024-12-06 | Feldschuh Michael Richard | Chief Executive Officer | 45,000 – | $0 | $0 | +1.24% | ||
| 2024-12-06 | Feldschuh Jonathan Adam | Chief Scientific Officer | 32,000 – | $0 | $0 | +1.24% | ||
| 2024-03-27 | Michel Robert J | Chief Financial Officer | 750 0.0161% | $8.70 | $6,525 | +3.15% | ||
| 2024-03-26 | Feldschuh Michael Richard | Chief Executive Office | 1,000 0.0199% | $8.13 | $8,130 | +2.43% | ||
| 2024-03-19 | Feldschuh Michael Richard | Chief Executive Officer | 647 0.0133% | $8.15 | $5,273 | +5.60% | ||
| 2024-03-10 | Feldschuh Michael Richard | Chief Executive Officer | 1,492 0.0308% | $7.72 | $11,518 | +7.52% | ||
| 2024-03-04 | Feuer Edward | director | 1,000 0.0212% | $7.21 | $7,210 | +23.37% | ||
| 2023-12-06 | Michel Robert J | Chief Financial Officer | 120 0.0025% | $7.75 | $930 | +12.14% | ||
| 2023-12-01 | Feldschuh Michael Richard | Chief Executive Officer | 800 0.0166% | $7.80 | $6,240 | +13.63% | ||
| 2023-12-01 | Michel Robert J | Chief Financial Officer | 180 0.0037% | $7.75 | $1,395 | +13.63% | ||
| 2023-11-24 | Michel Robert J | Chief Financial Officer | 500 0.0104% | $7.94 | $3,970 | +12.09% |
| Feldschuh Michael Richard | Chief Executive Officer | 213694 4.2411% | $2.27M | 38 | 1 | +34.09% |
| Feldschuh Jonathan Adam | Chief Scientific Officer | 53908 1.0699% | $571,424.80 | 2 | 1 | |
| Jefferies John | Chief Medical Officer | 23557 0.4675% | $249,704.20 | 2 | 0 | |
| Michel Robert J | Chief Financial Officer | 21050 0.4178% | $223,130.00 | 13 | 0 | +37.17% |
| FELDSCHUH JOSEPH | 10 percent owner | 2774455 55.0636% | $29.41M | 105 | 3 | +24.27% |
| Hudson Philip Nordan | director | 146200 2.9016% | $1.55M | 13 | 0 | |
| WILLENS ROBERT | director | 18164 0.3605% | $192,538.40 | 17 | 0 | +21.24% |
| WOLPOFF MARTIN S | director | 4000 0.0794% | $42,400.00 | 8 | 2 | +18.35% |
| DesRosiers Caleb | director | 3157 0.0627% | $33,464.20 | 1 | 0 | |
| Thompson Soren | VP, Business Development | 1950 0.0387% | $20,670.00 | 2 | 1 | +54.72% |
| MOUSSA ROBERT G | director | 1000 0.0198% | $10,600.00 | 2 | 0 | |
| Feuer Edward | director | 1000 0.0198% | $10,600.00 | 2 | 0 | +30.13% |
| LOMBARD JAMES A | director | 500 0.0099% | $5,300.00 | 1 | 0 | |
| Valentine Stephen | director | 500 0.0099% | $5,300.00 | 1 | 0 | |
| Meegan Diane Marie | Corporate Secretary | 500 0.0099% | $5,300.00 | 1 | 1 | |
| Engstrom Everis | Vice President | 500 0.0099% | $5,300.00 | 1 | 0 | |
| Goudie Joy S. | director | 300 0.006% | $3,180.00 | 1 | 0 | |
| Saxe Bernhard | director | 200 0.004% | $2,120.00 | 1 | 0 | |
| SLOVIN BRUCE | director | 0 0% | $0 | 0 | 6 |
Daxor Corporation (DXR) | $167,495 | 10 | 32.53% | $53.41M |
$8,662,717 | 6 | -49.85% | $3.62M | |
$858,500 | 3 | 13.15% | $1.13B | |
$524,992 | 2 | 18.45% | $5.51B | |
$34,477,719 | 2 | -9.33% | $44.82M |
| Increased Positions | 4 | +50% | 13,091 | +15.46% |
| Decreased Positions | 3 | -37.5% | 1,040 | -1.23% |
| New Positions | 3 | New | 13,090 | New |
| Sold Out Positions | <1 | Sold Out | 40 | Sold Out |
| Total Postitions | 9 | +12.5% | 96,709 | +14.23% |
| Vanguard Group Inc | $704.00 | 0.98% | 49,028 | 0 | 0% | 2025-09-30 |
| Renaissance Technologies Llc | $415.00 | 0.58% | 28,921 | +900 | +3.21% | 2025-09-30 |
| Morgan Stanley | $51.00 | 0.07% | 3,537 | -18 | -0.51% | 2025-09-30 |
| Sbi Securities Co., Ltd. | $45.00 | 0.06% | 3,128 | 0 | 0% | 2025-09-30 |
| Bank Of America Corp /De/ | $1.00 | <0.01% | 40 | +40 | New | 2025-09-30 |
| Jpmorgan Chase & Co | $0 | 0% | 4 | 0 | 0% | 2025-09-30 |
| Keyes, Stange & Wooten Wealth Management, Llc | $0 | 0% | 0 | -15,914 | Sold Out | 2025-09-30 |